Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)
Identifieur interne : 003A96 ( Main/Exploration ); précédent : 003A95; suivant : 003A97Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)
Auteurs : F. Tas ; F. Sen [Turquie] ; S. Keskin [Turquie] ; L. Kilic [Turquie]Source :
- Journal of the European Academy of Dermatology and Venereology [ 0926-9959 ] ; 2013-06.
Abstract
Background Classic Kaposi’s sarcoma (CKS) affects an elderly population; it is important to have effective treatment options with high activity and relatively low toxicity, and availability to be used for long periods.
Url:
DOI: 10.1111/j.1468-3083.2011.04404.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000C45
- to stream Istex, to step Curation: 000C45
- to stream Istex, to step Checkpoint: 000124
- to stream Main, to step Merge: 003B05
- to stream Main, to step Curation: 003A96
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)</title><author><name sortKey="Tas, F" sort="Tas, F" uniqKey="Tas F" first="F." last="Tas">F. Tas</name></author><author><name sortKey="Sen, F" sort="Sen, F" uniqKey="Sen F" first="F." last="Sen">F. Sen</name></author><author><name sortKey="Keskin, S" sort="Keskin, S" uniqKey="Keskin S" first="S." last="Keskin">S. Keskin</name></author><author><name sortKey="Kilic, L" sort="Kilic, L" uniqKey="Kilic L" first="L." last="Kilic">L. Kilic</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1AAFF4322434DC1B2D465784F08912917BE752C3</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1111/j.1468-3083.2011.04404.x</idno><idno type="url">https://api.istex.fr/document/1AAFF4322434DC1B2D465784F08912917BE752C3/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000C45</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C45</idno><idno type="wicri:Area/Istex/Curation">000C45</idno><idno type="wicri:Area/Istex/Checkpoint">000124</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000124</idno><idno type="wicri:doubleKey">0926-9959:2013:Tas F:oral:etoposide:as</idno><idno type="wicri:Area/Main/Merge">003B05</idno><idno type="wicri:Area/Main/Curation">003A96</idno><idno type="wicri:Area/Main/Exploration">003A96</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)</title><author><name sortKey="Tas, F" sort="Tas, F" uniqKey="Tas F" first="F." last="Tas">F. Tas</name><affiliation><wicri:noCountry code="no comma">E-mail: faruktas2002@yahoo.com</wicri:noCountry></affiliation></author><author><name sortKey="Sen, F" sort="Sen, F" uniqKey="Sen F" first="F." last="Sen">F. Sen</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Institute of Oncology, University of Istanbul, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Keskin, S" sort="Keskin, S" uniqKey="Keskin S" first="S." last="Keskin">S. Keskin</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Institute of Oncology, University of Istanbul, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author><author><name sortKey="Kilic, L" sort="Kilic, L" uniqKey="Kilic L" first="L." last="Kilic">L. Kilic</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Institute of Oncology, University of Istanbul, Istanbul</wicri:regionArea><wicri:noRegion>Istanbul</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of the European Academy of Dermatology and Venereology</title><title level="j" type="alt">JOURNAL OF EUROPEAN ACADEMY DERMATOLOGY VENEREOLOGY</title><idno type="ISSN">0926-9959</idno><idno type="eISSN">1468-3083</idno><imprint><biblScope unit="vol">27</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="789">789</biblScope><biblScope unit="page" to="792">792</biblScope><biblScope unit="page-count">4</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2013-06">2013-06</date></imprint><idno type="ISSN">0926-9959</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0926-9959</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Background Classic Kaposi’s sarcoma (CKS) affects an elderly population; it is important to have effective treatment options with high activity and relatively low toxicity, and availability to be used for long periods.</div></front></TEI><affiliations><list><country><li>Turquie</li></country></list><tree><noCountry><name sortKey="Tas, F" sort="Tas, F" uniqKey="Tas F" first="F." last="Tas">F. Tas</name></noCountry><country name="Turquie"><noRegion><name sortKey="Sen, F" sort="Sen, F" uniqKey="Sen F" first="F." last="Sen">F. Sen</name></noRegion><name sortKey="Keskin, S" sort="Keskin, S" uniqKey="Keskin S" first="S." last="Keskin">S. Keskin</name><name sortKey="Kilic, L" sort="Kilic, L" uniqKey="Kilic L" first="L." last="Kilic">L. Kilic</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A96 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A96 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1AAFF4322434DC1B2D465784F08912917BE752C3
|texte= Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)
}}
| This area was generated with Dilib version V0.6.31. |  |